UBE2N and cancer: In practical terms, we have developed small molecules that can effectively and selectively antagonize the Ubc13-Uev1 interaction and inhibit K63 polyubiquitylation in both yeast and mammalian cells, and we have shown that these compounds can be used in combination therapy schemes as antitumoral agents in cultured and animal models of cancer.